High dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

BACKGROUND: Ursodeoxycholic acid (UDCA) in a dose of 28–30 mg/kg/day increases the likelihood of clinical deterioration of primary sclerosing cholangitis (PSC) patients. AIM: Our aim was to compare the risk of adverse clinical endpoints in patients with varying disease status. METHODS: We reviewed r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Imam, Mohamad H., Sinakos, Emmanouil, Gossard, Andrea A., Kowdley, Kris V., Luketic, Velimir A. C., Harrison, M. Edwyn, McCashland, Timothy, Befeler, Alex S., Harnois, Denise, Jorgensen, Roberta, Petz, Jan, Keach, Jill, DeCook, Alisha C., Enders, Felicity, Lindor, Keith D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3752281/
https://ncbi.nlm.nih.gov/pubmed/21957881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2036.2011.04863.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados